Adc Therapeutics Sa rose 4.45% in after-hours trading, with Innate Pharma reporting its first half 2025 business update. The company highlighted key milestones anticipated over the next 12 months and its focus on progressing promising clinical assets and advancing next ADCs toward development.
Comments
No comments yet